AXOGEN INC (AXGN) Stock Fundamental Analysis
USA - NASDAQ:AXGN - US05463X1063 - Common Stock
17.6 USD
+0.4 (+2.33%)
17.59 USD
-0.01 (-0.06%)
We assign a fundamental rating of 5 out of 10 to AXGN. AXGN was compared to 190 industry peers in the Health Care Equipment & Supplies industry. AXGN has only an average score on both its financial health and profitability. AXGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AXGN had positive earnings in the past year.
In the past year AXGN had a positive cash flow from operations.
AXGN had negative earnings in each of the past 5 years.
In the past 5 years AXGN reported 4 times negative operating cash flow.
1.2 Ratios
AXGN has a better Return On Assets (-2.27%) than 67.37% of its industry peers.
AXGN has a better Return On Equity (-4.15%) than 69.47% of its industry peers.
AXGN has a better Return On Invested Capital (0.75%) than 66.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -4.15% | ||
| ROIC | 0.75% |
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AXGN's Operating Margin of 0.84% is fine compared to the rest of the industry. AXGN outperforms 65.26% of its industry peers.
AXGN has a better Gross Margin (74.27%) than 85.79% of its industry peers.
AXGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.84% | ||
| PM (TTM) | N/A | ||
| GM | 74.27% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AXGN is destroying value.
AXGN has more shares outstanding than it did 1 year ago.
AXGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AXGN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.56 indicates that AXGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.56, AXGN is in the better half of the industry, outperforming 77.37% of the companies in the same industry.
AXGN has a debt to FCF ratio of 13.85. This is a negative value and a sign of low solvency as AXGN would need 13.85 years to pay back of all of its debts.
AXGN has a Debt to FCF ratio of 13.85. This is in the better half of the industry: AXGN outperforms 72.11% of its industry peers.
AXGN has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
AXGN's Debt to Equity ratio of 0.43 is in line compared to the rest of the industry. AXGN outperforms 43.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 13.85 | ||
| Altman-Z | 4.56 |
ROIC/WACC0.08
WACC8.97%
2.3 Liquidity
AXGN has a Current Ratio of 4.14. This indicates that AXGN is financially healthy and has no problem in meeting its short term obligations.
AXGN's Current ratio of 4.14 is fine compared to the rest of the industry. AXGN outperforms 70.53% of its industry peers.
A Quick Ratio of 2.67 indicates that AXGN has no problem at all paying its short term obligations.
AXGN has a Quick ratio of 2.67. This is in the better half of the industry: AXGN outperforms 64.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.14 | ||
| Quick Ratio | 2.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 500.00% over the past year.
AXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.17%.
The Revenue has been growing by 11.92% on average over the past years. This is quite good.
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%18.26%
3.2 Future
Based on estimates for the next years, AXGN will show a very strong growth in Earnings Per Share. The EPS will grow by 50.38% on average per year.
The Revenue is expected to grow by 16.23% on average over the next years. This is quite good.
EPS Next Y100.08%
EPS Next 2Y92.71%
EPS Next 3Y90.78%
EPS Next 5Y50.38%
Revenue Next Year17.84%
Revenue Next 2Y16.84%
Revenue Next 3Y15.02%
Revenue Next 5Y16.23%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 73.33, the valuation of AXGN can be described as expensive.
Based on the Price/Earnings ratio, AXGN is valued a bit cheaper than the industry average as 66.32% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.41. AXGN is valued rather expensively when compared to this.
AXGN is valuated quite expensively with a Price/Forward Earnings ratio of 36.45.
Based on the Price/Forward Earnings ratio, AXGN is valued a bit cheaper than the industry average as 71.58% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of AXGN to the average of the S&P500 Index (22.87), we can say AXGN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.33 | ||
| Fwd PE | 36.45 |
4.2 Price Multiples
63.16% of the companies in the same industry are more expensive than AXGN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AXGN is valued a bit cheaper than the industry average as 67.89% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 233.7 | ||
| EV/EBITDA | 86.03 |
4.3 Compensation for Growth
AXGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AXGN's earnings are expected to grow with 90.78% in the coming years.
PEG (NY)0.73
PEG (5Y)N/A
EPS Next 2Y92.71%
EPS Next 3Y90.78%
5. Dividend
5.1 Amount
AXGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.6
+0.4 (+2.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners86.63%
Inst Owner Change1.79%
Ins Owners0.92%
Ins Owner Change-0.41%
Market Cap809.78M
Analysts84.29
Price Target25.37 (44.15%)
Short Float %5.86%
Short Ratio1.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-68.39%
Min EPS beat(2)-222.55%
Max EPS beat(2)85.77%
EPS beat(4)3
Avg EPS beat(4)275.79%
Min EPS beat(4)-222.55%
Max EPS beat(4)1125.49%
EPS beat(8)7
Avg EPS beat(8)185.94%
EPS beat(12)11
Avg EPS beat(12)146.94%
EPS beat(16)14
Avg EPS beat(16)116.93%
Revenue beat(2)1
Avg Revenue beat(2)2%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)5.47%
Revenue beat(4)2
Avg Revenue beat(4)1.26%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)5.47%
Revenue beat(8)5
Avg Revenue beat(8)1.38%
Revenue beat(12)7
Avg Revenue beat(12)0.53%
Revenue beat(16)7
Avg Revenue beat(16)-0.53%
PT rev (1m)2.58%
PT rev (3m)2.58%
EPS NQ rev (1m)2.39%
EPS NQ rev (3m)7.5%
EPS NY rev (1m)0%
EPS NY rev (3m)22.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.33 | ||
| Fwd PE | 36.45 | ||
| P/S | 3.98 | ||
| P/FCF | 233.7 | ||
| P/OCF | 112.67 | ||
| P/B | 7.21 | ||
| P/tB | 7.63 | ||
| EV/EBITDA | 86.03 |
EPS(TTM)0.24
EY1.36%
EPS(NY)0.48
Fwd EY2.74%
FCF(TTM)0.08
FCFY0.43%
OCF(TTM)0.16
OCFY0.89%
SpS4.42
BVpS2.44
TBVpS2.31
PEG (NY)0.73
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -4.15% | ||
| ROCE | 0.95% | ||
| ROIC | 0.75% | ||
| ROICexc | 0.9% | ||
| ROICexgc | 0.94% | ||
| OM | 0.84% | ||
| PM (TTM) | N/A | ||
| GM | 74.27% | ||
| FCFM | 1.7% |
ROA(3y)-10.24%
ROA(5y)-11.1%
ROE(3y)-20.3%
ROE(5y)-20.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-1.5%
F-Score6
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 13.85 | ||
| Debt/EBITDA | 5.16 | ||
| Cap/Depr | 49.09% | ||
| Cap/Sales | 1.83% | ||
| Interest Coverage | 0.24 | ||
| Cash Conversion | 77.33% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.14 | ||
| Quick Ratio | 2.67 | ||
| Altman-Z | 4.56 |
F-Score6
WACC8.97%
ROIC/WACC0.08
Cap/Depr(3y)337.29%
Cap/Depr(5y)669.18%
Cap/Sales(3y)9.04%
Cap/Sales(5y)13.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y100.08%
EPS Next 2Y92.71%
EPS Next 3Y90.78%
EPS Next 5Y50.38%
Revenue 1Y (TTM)17.17%
Revenue growth 3Y13.72%
Revenue growth 5Y11.92%
Sales Q2Q%18.26%
Revenue Next Year17.84%
Revenue Next 2Y16.84%
Revenue Next 3Y15.02%
Revenue Next 5Y16.23%
EBIT growth 1Y114.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1384.37%
EBIT Next 3Y205.47%
EBIT Next 5YN/A
FCF growth 1Y112.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y211.25%
OCF growth 3YN/A
OCF growth 5YN/A